Trajan continues to provide essential products and services to the scientific and healthcare community worldwide.
To our customers, partners, industry and academic colleagues - if there is anything Trajan can do to assist you during this time, please let us know.
- Stephen Tomisich, CEO.
Trajan designs, automates and delivers devices that enhance scientific measurement.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.